Key result
MIF protects against myocardial ischaemia/reperfusion injury by activating AMPK signalling and reducing oxidative stress.
Answers are grounded in this paper and cite their sources.
Acute myocardial infarction (AMI) remains one of the leading causes of death in the developed world. There is emerging evidence that the cytokine macrophage migration inhibitory factor (MIF) is a crucial player in AMI. Cardioprotection by MIF is likely to be a multifactorial phenomenon mediated by receptor-mediated signalling processes, intracellular protein-protein interactions, and enzymatic redox regulation. Co-ordinating several pathways in the ischaemic heart, MIF contributes to receptor-mediated regulation of cardioprotective AMP-activated protein kinase signalling, inhibition of pro-apoptotic cascades, and the reduction of oxidative stress in the post-ischaemic heart. Moreover, the cardioprotective properties of MIF are modulated by S-nitros(yl)ation. These effects in the pathophysiology of myocardial ischaemia/reperfusion injury qualify MIF as a promising therapeutic target in the future. We here summarize the findings of experimental and clinical studies and emphasize the therapeutic potential of MIF in AMI.
No takes yet. Share an insight, caveat, or question.
Rassaf et al. (2014) conducted a review in Acute myocardial infarction and myocardial ischaemia/reperfusion injury. Macrophage migration inhibitory factor (MIF) was evaluated. Macrophage migration inhibitory factor (MIF) provides cardioprotection in myocardial ischaemia/reperfusion injury via AMPK signalling, apoptosis inhibition, and oxidative stress reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: